Palovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease with an estimated prevalence of 1.36 per million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback